Brokerages Expect Dynavax Technologies Co. (NASDAQ:DVAX) to Announce $0.22 Earnings Per Share – Defense World
Posted by admin on Jun 3rd, 2022 
Wall Street brokerages expect Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) to post earnings per share of $0.22 for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Dynavax Technologies’ earnings, with the lowest EPS estimate coming in at $0.21 and the highest estimate coming in at $0.23. Dynavax Technologies posted earnings per share of $0.02 in the same quarter last year, which would suggest a positive year over year growth rate of 1,000%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Dynavax Technologies will report full year earnings of $1.14 per share for the current financial year, with EPS estimates ranging from $1.10 to $1.20. For the next year, analysts anticipate that the firm will report earnings of $0.02 per share, with EPS estimates ranging from ($0.93) to $0.60. Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.02). Dynavax Technologies had a net margin of 23.12% and a return on equity of 87.36%. The business had revenue of $113.99 million for the quarter, compared to analyst estimates of $117.76 million. During the same period in the prior year, the business earned $0.01 EPS.
DVAX has been the subject of several research reports. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Thursday, May 12th. TheStreet raised Dynavax Technologies from a “d+” rating to a “c” rating in a report on Wednesday, March 30th. Finally, Zacks Investment Research downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, March 1st. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $21.00.
In related news, insider Justin Burgess sold 6,000 shares of the firm’s stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $10.00, for a total value of $60,000.00. Following the transaction, the insider now owns 3,854 shares in the company, valued at $38,540. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.31% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Federated Hermes Inc. grew its position in Dynavax Technologies by 2.0% in the first quarter. Federated Hermes Inc. now owns 16,537,838 shares of the biopharmaceutical company’s stock valued at $179,270,000 after acquiring an additional 330,000 shares during the last quarter. State Street Corp grew its position in Dynavax Technologies by 36.1% in the first quarter. State Street Corp now owns 8,498,732 shares of the biopharmaceutical company’s stock valued at $92,126,000 after acquiring an additional 2,253,376 shares during the last quarter. Chicago Capital LLC grew its position in Dynavax Technologies by 2.1% in the first quarter. Chicago Capital LLC now owns 5,855,712 shares of the biopharmaceutical company’s stock valued at $63,476,000 after acquiring an additional 121,678 shares during the last quarter. Marshall Wace LLP bought a new position in Dynavax Technologies in the third quarter valued at about $98,295,000. Finally, Fisher Asset Management LLC grew its position in Dynavax Technologies by 8.5% in the fourth quarter. Fisher Asset Management LLC now owns 3,605,779 shares of the biopharmaceutical company’s stock valued at $50,733,000 after acquiring an additional 282,002 shares during the last quarter. Institutional investors own 76.80% of the company’s stock.
Dynavax Technologies stock traded up $0.17 during mid-day trading on Thursday, hitting $12.09. 2,483,182 shares of the company’s stock traded hands, compared to its average volume of 2,373,644. The firm has a 50 day simple moving average of $10.29 and a two-hundred day simple moving average of $12.19. Dynavax Technologies has a fifty-two week low of $7.26 and a fifty-two week high of $21.39. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of 21.98 and a beta of 1.41. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.02 and a quick ratio of 1.85.
Dynavax Technologies Company Profile (Get Rating)
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Read More
Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dynavax Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.
Brokerages Anticipate BrightView Holdings, Inc. (NYSE:BV) to Post $0.49 EPS
STAG Industrial, Inc. (NYSE:STAG) Expected to Announce Earnings of $0.53 Per Share